Stryker And St. Jude Acquisitions Signal Year-end Uptick In Device M&A

The M&A market for medtech companies had already slowly started to climb off the mat after last year's collapse when Stryker and St. Jude Medical closed on two $1 billion-plus acquisitions. Still, Stryker's bid to acquire the neurovascular business of Boston Scientific and St. Jude's offer for structural heart disease company AGA Medical demonstrate how deep strategic acquirers are willing to dig to establish themselves in new markets.The combined price tag of $2.7 billion guaranteed that 2010 will be a better year for medical device mergers and acquisitions than 2009, at least as measured by disclosed prices paid.

The merger and acquisition market for medtech companies had already slowly started to climb off the mat after last year's collapse when Stryker Corp. and St. Jude Medical Inc. closed on two $1 billion-plus acquisitions. Still, Stryker's $1.4 billion bid to acquire the neurovascular business of Boston Scientific Corp. and St. Jude's $1.3 billion offer for structural heart disease company AGA Medical Holdings Inc. demonstrate how deep strategic acquirers are willing to dig to establish themselves in new markets. [See Deal][See Deal] In acquiring AGA, St. Jude agreed to pay $20.80 per share, a 41% premium to the pre-announcement share price.

The combined price tag of $2.7 billion guaranteed that 2010 will be a better year for medical device mergers and acquisitions than 2009, at least as measured by disclosed prices paid. An analysis of data in Elsevier's Strategic Transactions recorded $11.7 billion paid out for medical device acquisitions last year versus $13.2 billion through the end of October this year. That dollar total came in on 73 deals this year versus 98 in all 2009, so acquirers are paying more per deal. (In both years roughly one-third of the total deals didn't make the terms public.) Michael J

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By 

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Rising Leaders 2025: Christina Ziegenberg On Keeping Medtechs Competitive And MDR Compliant

 
• By 

Good medical device regulation brings balance and builds bridges between healthcare stakeholders. It also accords equal priority to innovation and patient safety. A zero-risk policy cannot achieve these goals, says Christina Ziegenberg, BVMed’s head of regulatory affairs of six years.